Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.33 |
| ▸ | F11 | P03951 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16971357 | 0.89 | F11 (0.37) | RXRAGRIN1GRIN2BF11NOTUM | |
| SCHEMBL16974697 | 0.87 | NOTUM (0.43) | RXRAGRIN1GRIN2BF11NOTUM | |
| SCHEMBL16971884 | 0.86 | GABRA2 (0.36) | RXRAGRIN1GRIN2BF11NOTUM | |
| SCHEMBL16972064 | 0.85 | NOTUM (0.45) | RXRAGRIN1GRIN2BF11NOTUM | |
| SCHEMBL16974539 | 0.84 | RXRA (0.35) | RXRAGRIN1GRIN2BF11NOTUM | |
| SCHEMBL16971741 | 0.84 | NOTUM (0.35) | RXRAGRIN1GRIN2BF11NOTUM | |
| SCHEMBL16971771 | 0.84 | F11 (0.38) | RXRAGRIN1GRIN2BF11NOTUM | |
| SCHEMBL16971962 | 0.84 | RXRA (0.33) | RXRAGRIN1GRIN2BF11NOTUM | |
| SCHEMBL30271797 | 0.84 | RXRA (0.33) | RXRAGRIN1GRIN2BF11NOTUM | |
| SCHEMBL16971854 | 0.84 | NOTUM (0.46) | RXRAGRIN1GRIN2BNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053247-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-10676477-B2 | Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200055854-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-20 | — | — | US | disclosed |
| US-10336754-B2 | Pyrimidinones as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336730-B2 | Substituted glycine derived FXIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-10287288-B2 | Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties | BRISTOL-MYERS SQUIBB (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180222889-A1 | NOVEL SUBSTITUTED GLYCINE DERIVED FXIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180215755-A1 | FACTOR XIA MACROCYCLIC INHIBITORS BEARING ALKYL OR CYCLOALKYL P2' MOIETIES | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180186795-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-07-05 | — | — | US | disclosed |
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
| US-9777001-B2 | Macrocycles with aromatic P2′ groups as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170096429-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053247-B2 | Pyrimidinones as factor XIA inhibitors | TFPI, TFPI2, F11 | RXRA 4700/4885GRIN1 2591/4885GRIN2B 3080/4885 |
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | RXRA 4578/4885GRIN1 4581/4885GRIN2B 4350/4885 |
| US-20180215755-A1 | FACTOR XIA MACROCYCLIC INHIBITORS BEARING ALKYL OR CYCLOALKYL P2' MOIETIES | TFPI, TFPI2, F11 | RXRA 4563/4885GRIN1 4473/4885GRIN2B 4194/4885 |
| US-20180186795-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | RXRA 4646/4885GRIN1 2872/4885GRIN2B 2964/4885 |
| US-20200055854-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | RXRA 4700/4885GRIN1 2591/4885GRIN2B 3080/4885 |
| US-10336730-B2 | Substituted glycine derived FXIA inhibitors | F2, TFPI, TFPI2 | RXRA 4791/4885GRIN1 592/4885GRIN2B 902/4885 |
| US-20170096429-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | RXRA 4183/4885GRIN1 4619/4885GRIN2B 4351/4885 |
| US-10676477-B2 | Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group | TFPI, TFPI2, F2 | RXRA 4270/4885GRIN1 4685/4885GRIN2B 4534/4885 |
| US-20180222889-A1 | NOVEL SUBSTITUTED GLYCINE DERIVED FXIA INHIBITORS | TFPI, TFPI2, F2 | RXRA 4809/4885GRIN1 497/4885GRIN2B 666/4885 |
| US-10287288-B2 | Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties | TFPI, TFPI2, F11 | RXRA 4563/4885GRIN1 4473/4885GRIN2B 4194/4885 |
| US-10336754-B2 | Pyrimidinones as factor XIa inhibitors | TFPI, TFPI2, F2 | RXRA 4646/4885GRIN1 2872/4885GRIN2B 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.